ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm currently has a $4.25 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 5.46% from the company’s current price.
According to Zacks, “ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. “
Get ESSA Pharma alerts:
A number of other equities analysts have also weighed in on EPIX. Bloom Burton upgraded shares of ESSA Pharma from a “hold” rating to a “buy” rating in a report on Thursday, January 18th. ValuEngine upgraded shares of ESSA Pharma from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, HC Wainwright began coverage on shares of ESSA Pharma in a research note on Monday, March 26th. They set a “buy” rating and a $0.70 target price for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $2.48.
NASDAQ EPIX traded up $0.16 during mid-day trading on Thursday, reaching $4.03. The stock had a trading volume of 3 shares, compared to its average volume of 33,621. ESSA Pharma has a 1 year low of $3.80 and a 1 year high of $4.03. The firm has a market cap of $22.24 million, a P/E ratio of -0.50 and a beta of 1.68. The company has a quick ratio of 0.62, a current ratio of 0.62 and a debt-to-equity ratio of -0.84.
ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.07) earnings per share for the quarter. equities analysts expect that ESSA Pharma will post -1.73 earnings per share for the current fiscal year.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com